Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1991-8-15
|
pubmed:abstractText |
The pharmacokinetics of 2',3'-dideoxyinosine (ddI) were investigated in four adult male beagle dogs that received 15-min infusions of 20-, 50-, and 100-mg/kg doses in a randomized crossover study design. Plasma and urine samples were collected for 10 and 24 h, respectively, and assayed for ddI by high-performance liquid chromatographic methods. The mean maximum concentrations of drug in plasma at the end of 15-min infusions for the 20-, 50-, and 100-mg/kg doses were 33.3, 90.0, and 202 micrograms/ml, respectively. Area under the concentration-time curve data deviated significantly from linearity. The mean total clearance for the low dose (250 ml/min) was significantly greater than that for the high dose (190 ml/min). Renal clearance, which averaged between 98 and 116 ml/min, was dose independent. Renal clearance implied that nonrenal clearance decreased at the high dose (92 ml/min) when compared with that of the low dose (134 ml/min). The average urinary recovery of ddI for the high dose (51.2% of dose) was significantly greater than that for the low dose (45.8%). The volume of distribution at steady state averaged between 7.6 and 10.5 liters and decreased with increasing dose; however, it was not statistically significant. The mean half-life and mean residence time were invariant with respect to dose and averaged between 0.94 and 1.07 h and 0.61 and 0.71 h, respectively. In this dose range, ddI pharmacokinetics are dose dependent.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-2497744,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-2502840,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-2787472,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-3006077,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-3056844,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-3120727,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-657710,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-6766310,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-7166738,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1906259-7252794
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0066-4804
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
610-4
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:1906259-Animals,
pubmed-meshheading:1906259-Antiviral Agents,
pubmed-meshheading:1906259-Chromatography, High Pressure Liquid,
pubmed-meshheading:1906259-Didanosine,
pubmed-meshheading:1906259-Dogs,
pubmed-meshheading:1906259-HIV,
pubmed-meshheading:1906259-Half-Life,
pubmed-meshheading:1906259-Injections, Intravenous,
pubmed-meshheading:1906259-Male
|
pubmed:year |
1991
|
pubmed:articleTitle |
Pharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs.
|
pubmed:affiliation |
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Company, Syracuse, New York 13221-4755.
|
pubmed:publicationType |
Journal Article
|